Literature DB >> 31789820

The Clinicopathologic Characteristics and Complement Activation of Antineutrophil Cytoplasmic Antibody-associated Vasculitides With Glomerular IgA Deposition.

Yanhong Ma1,2,3, Liangliang Chen1,2,3, Ying Xu1,2,3, Quan Han1,2,3, Binfeng Yu1,2,3, Jie Zhao1,2,3, Zhou Hua4, Yi Yang1,2,3, Jianghua Chen1,2,3, Fei Han1,2,3.   

Abstract

The renal injury caused by antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are characterized by few or no immune deposits in glomerulus. A growing number of AAV patients with glomerular immunoglobulin (Ig)A deposits have been reported. We retrospectively investigated all AAV patients with glomerular IgA deposits diagnosed in our center. Serum galactose-deficient IgA1 (Gd-IgA1) level and glomerular Gd-IgA1 and IgA staining were measured. Moreover, we detected complement pathway components in their sera. A total of 168 AAV patients were enrolled, including 26 patients with glomerular IgA deposition and 142 patients with pauci-immune-complex deposition. The AAV patients with IgA deposition had a tendency of lower systemic disease activity, presenting with lower erythrocyte sedimentation rate, lower myeloperoxidase-ANCA, and tendency of lower C reactive protein and Birmingham Vasculitis Activity Score. For renal injury, there were no significant differences in clinical data, pathologic parameters, or renal outcome between groups. The serum level of Gd-IgA1 and intensity of glomerular Gd-IgA1 staining in IgA deposition AAV patients were similar to IgA nephropathy patients. All patients in the IgA nephropathy group and AAV groups with or without IgA deposition had the activation of the alternative complement pathway, whereas AAV patients with IgA deposition also had the activation of the classic complement pathway. Correlation analysis showed serum C1q level correlated directly with serum globulin and IgA levels. In conclusion, AAV patients with IgA deposition had the basis of IgA nephropathy and may present lower systemic disease activity. But it differs from pauci-immune AAV or IgA nephropathy by the possible activation of the classic complement pathway.

Entities:  

Year:  2020        PMID: 31789820     DOI: 10.1097/PAI.0000000000000819

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  4 in total

1.  Predictors of poor prognosis in ANCA-associated vasculitis (AAV): a single-center prospective study of inpatients in China.

Authors:  Ronglin Gao; Zhenzhen Wu; Xianghuai Xu; Jincheng Pu; Shengnan Pan; Youwei Zhang; Shuqi Zhuang; Lufei Yang; Yuanyuan Liang; Jiamin Song; Jianping Tang; Xuan Wang
Journal:  Clin Exp Med       Date:  2022-10-16       Impact factor: 5.057

2.  Coexistence of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and IgA nephropathy.

Authors:  Yong Zhong; Xiangcheng Xiao; Qi Xiong; Wei Lin; Chanjuan Shen; Ting Meng; Rong Tang; Joshua D Ooi; Peter J Eggenhuizen; Jinbiao Chen; Wannian Nie; Xia Li; Qiaoling Zhou; Ping Xiao
Journal:  Immunol Res       Date:  2022-10-13       Impact factor: 4.505

3.  Glomerular Immune Deposition in MPO-ANCA Associated Glomerulonephritis Is Associated With Poor Renal Survival.

Authors:  Wei Lin; Chanjuan Shen; Yong Zhong; Joshua D Ooi; Peter Eggenhuizen; Ya-Ou Zhou; Hui Luo; Jing Huang; Jin-Biao Chen; Ting Wu; Ting Meng; Zhou Xiao; Xiang Ao; Weisheng Peng; Rong Tang; Hongling Yin; Xiangcheng Xiao; Qiaoling Zhou; Ping Xiao
Journal:  Front Immunol       Date:  2021-03-25       Impact factor: 7.561

4.  IgA nephropathy in patients with serum anti-neutrophil cytoplasmic autoantibody (ANCA) positivity: case series.

Authors:  Cristiane Bitencourt Dias; Lectícia Barbosa Jorge; Viktoria Woronik; Lívia Barreira Cavalcante; Luis Yu
Journal:  J Bras Nefrol       Date:  2022 Jan-Mar
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.